natgillin/translations-raw huggingface dataset:
Human normal immunoglobulin 10%
Normalni ljudski imunoglobulin 10
Human normal immunoglobulin 100 mg (purity of at least 98% IgG)
Ljudski normalni imunoglobulin 100 mg (čistoće najmanje 98% IgG)
Human normal immunoglobulin 100 mg IgG purity ................................. ≥ 98%
Ljudski normalni imunoglobulin 100 mg IgG čistoće………………….. ≥ 98
Human normal immunoglobulin 100 mg.
Ljudski normalni imunoglobulin 100 mg.
Human normal immunoglobulin contains mainly immunoglobulin G (IgG) with a broad spectrum of antibodies against infectious agents.
Ljudski normalni imunoglobulin sadrži uglavnom imunoglobulin G (IgG) sa širokim spektrom protutijela protiv zaraznih agensa.
Human normal immunoglobulin is immediately and completely bioavailable in the recipient’s circulation after intravenous administration.
Ljudski normalni imunoglobulin je nakon intravenske primjene odmah i potpuno biološki raspoloživ u cirkulaciji primatelja.
Human normal immunoglobulin is immediately and completely bioavailable in the recipient’s circulation after intravenous administration.
Normalni ljudski imunoglobulin je nakon intravenske primjene odmah i u potpunosti bioraspoloživ u cirkulaciji primatelja.
Human normal immunoglobulin should be infused intravenously at an initial infusion rate of 0.3 ml/kg bw/hr for approximately 30 min.
Ljudski normalni imunoglobulin primjenjuje se intravenski infuzijom početne brzine 0,3 ml/kg TT/sat u trajanju oko 30 minuta.
Human normal immunoglobulin vial: 100 mg/ml, at least 98% is IgG Maximum immunoglobulin A (IgA) content: 140 micrograms/ml.
Bočica normalnog ljudskog imunoglobulina: 100 mg/ml, najmanje 98% IgG-a Maksimalni sadržaj imunoglobulina A (IgA): 140 mikrograma/ml.
Human normal immunoglobulin ………..
Normalni ljudski imunoglobulin ………..
Human normal immunoglobulin …………..100 mg (purity of at least 97% IgG)
Normalni ljudski imunoglobulin…………..100 mg (pročišćen do najmanje 97% IgG)
Human normal immunoglobulin...................100 mg (purity of at least 98% IgG)
Normalni ljudski imunoglobulin..................100 mg (čistoće od najmanje 98% IgG-a)
Human paediatric patients are at increased risk for bone and teeth effects as compared to adults, as these changes, including inhibition of growth (shortened limbs), fragile bones and remodelling of teeth, were present in juvenile rats at ≥ 10 mg/kg/day (equal to approximately 0.1-0.2 times the clinical exposure based on AUC in adult humans) (see section 4.4).
Djeca su u povećanom riziku za učinak na kost i zube u usporedbi s odraslim ljudima, jer su ove promjene, uključujući inhibiciju rasta (skraćeni udovi), krhke kosti i remodeliranje zuba, bile prisutne u mladih štakora pri ≥10 mg/kg/dan (jednako kao približno 0,1-0,2 puta kliničke izloženosti na temelju AUC u odraslih ljudi) (vidjeti dio 4.4).
Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed)
Cjepivo protiv humanog papilomavirusa [tipova 16, 18] (rekombinantno, s adjuvansom, adsorbirano)
Human Papillomavirus1 Type 6 L1 protein2,3 20 micrograms Human Papillomavirus1 Type 11 L1 protein2,3 40 micrograms Human Papillomavirus1 Type 16 L1 protein2,3 40 micrograms Human Papillomavirus1 Type 18 L1 protein2,3 20 micrograms
humani papilomavirus1 tip 6 L1 protein2, 3 20 mikrograma humani papilomavirus1 tip 11 L1 protein2, 3 40 mikrograma humani papilomavirus1 tip 16 L1 protein2, 3 40 mikrograma humani papilomavirus1 tip 18 L1 protein2, 3 20 mikrograma
Human Papillomavirus1 Type 6 L1 protein2,3 20 micrograms Human Papillomavirus1 Type 11 L1 protein2,3 40 micrograms Human Papillomavirus1 Type 16 L1 protein2,3 40 micrograms Human Papillomavirus1 Type 18 L1 protein2,3 20 micrograms.
humani papilomavirus1 tip 6 L1 protein2, 3 20 mikrograma humani papilomavirus1 tip 11 L1 protein2, 3 40 mikrograma humani papilomavirus1 tip 16 L1 protein2, 3 40 mikrograma humani papilomavirus1 tip 18 L1 protein2, 3 20 mikrograma.
Human Papillomavirus1 Type 6 L1 protein2,3 30 micrograms Human Papillomavirus1 Type 11 L1 protein2,3 40 micrograms Human Papillomavirus1 Type 16 L1 protein2,3 60 micrograms Human Papillomavirus1 Type 18 L1 protein2,3 40 micrograms Human Papillomavirus1 Type 31 L1 protein2,3 20 micrograms Human Papillomavirus1 Type 33 L1 protein2,3 20 micrograms Human Papillomavirus1 Type 45 L1 protein2,3 20 micrograms Human Papillomavirus1 Type 52 L1 protein2,3 20 micrograms Human Papillomavirus1 Type 58 L1 protein2,3 20 micrograms
humani papilomavirus1 tip 6 L1 protein2, 3 30 mikrograma humani papilomavirus1 tip 11 L1 protein2, 3 40 mikrograma humani papilomavirus1 tip 16 L1 protein2, 3 60 mikrograma humani papilomavirus1 tip 18 L1 protein2, 3 40 mikrograma humani papilomavirus1 tip 31 L1 protein2, 3 20 mikrograma humani papilomavirus1 tip 33 L1 protein2, 3 20 mikrograma humani papilomavirus1 tip 45 L1 protein2, 3 20 mikrograma humani papilomavirus1 tip 52 L1 protein2, 3 20 mikrograma humani papilomavirus1 tip 58 L1 protein2, 3 20 mikrograma
Human plasma protein binding is approximately 75% following a single dose of Victrelis 800 mg.
Nakon jednokratne doze lijeka Victrelis od 800 mg, vezanje na proteine u plazmi u ljudi iznosi približno 75%.
Human plasma protein...................................................................................................................
Protein ljudske plazme ...............................................................
Human rotavirus RIX4414 strain (live, attenuated) not less than 106.0 CCID50
Human rotavirus soj RIX4414 (živi, atenuirani) ne manje od 106,0 CCID50
Human rotavirus RIX4414 strain (live, attenuated) not less than 106.0 CCID50
Humani rotavirus soj RIX4414 (živi, atenuirani) ne manje od 106,0 CCID50
Human rotavirus RIX4414 strain (live, attenuated)* not less than 106.0 CCID50
Humani rotavirus soj RIX4414 (živi, atenuirani)* ne manje od 106,0 CCID50
Human serum albumin Dibasic sodium phosphate Monobasic sodium phosphate Sodium chloride
ljudski serumski albumin natrijev hidrogenfosfat natrijev dihidrogenfosfat natrijev klorid
Human serum albumin, sodium chloride, di- and monobasic sodium phosphate.
Ljudski serumski albumin, natrijev klorid, natrijev hidrogenfosfat i natrijev dihidrogenfosfat.
Human studies evaluating the interaction of safinamide with CYP1A2 and CYP3A4 substrates (caffeine and midazolam), did not demonstrate any clinically significant effects on the pharmacokinetic profile of safinamide.
Ispitivanja u ljudi koja procjenjuju interakciju safinamida sa CYP1A2 i CYP3A4 supstratima (kofeinom i midazolamom), nisu pokazala nikakve klinički značajne učinke na farmakokinetički profil safinamida.
Human thrombin
Humani trombin
Human Thrombin
Ljudski trombin
Human thrombin:
Humani trombin:
Human von Willebrand factor
humani von Willebrandov faktor
Humira ( N = 30)
Humira (N=30)
Humira (N = 30)
Humira (N=30)
Humira / MTX (N = 38)
Humira/MTX (N=38)
Humira /MTX (N = 38)
Humira/MTX (N=38)
Humira 0.8 mg/kg eow N=38
Humira 0,8 mg/kg svaki drugi tjedan
Humira 40 mg solution for injection in pre-filled pen
Humira 40 mg otopina za injekciju u napunjenoj brizgalici
Humira 40 mg solution for injection in pre-filled pen is supplied as a sterile solution of 40 mg adalimumab dissolved in 0.4 ml solution.
Humira 40 mg otopina za injekciju u napunjenoj brizgalici dolazi kao sterilna otopina s 40 mg adalimumaba otopljenog u 0,4 ml otopine.
Humira 40 mg solution for injection in pre-filled syringe
Humira 40 mg otopina za injekciju u napunjenoj štrcaljki
Humira 40 mg solution for injection in pre-filled syringe is supplied as a sterile solution of 40 mg adalimumab dissolved in 0.4 ml solution.
Humira 40 mg otopina za injekciju u napunjenoj štrcaljki dolazi kao sterilna otopina s 40 mg adalimumaba otopljenog u 0,4 ml otopine.
Humira 40 mg solution for injection in pre-filled syringe with needleguard
Humira 40 mg otopina za injekciju u napunjenoj štrcaljki sa štitnikom za iglu
Humira 40 mg solution for injection in pre-filled syringe with needleguard adalimumab
Humira 40 mg otopina za injekciju u napunjenoj štrcaljki sa štitnikom za iglu adalimumab
Humira 40 mg solution for injection in single-use pre-filled pen for patient use containing a pre-filled syringe.
Humira 40 mg otopina za injekciju u napunjenoj brizgalici za jednokratnu primjenu, za uporabu kod bolesnika, a koja sadrži napunjenu štrcaljku.
Humira 40 mg solution for injection in single-use pre-filled pen for patient use containing a pre-filled syringe.
Humira 40 mg otopina za injekciju u napunjenoj brizgalici za primjenu u bolesnika koja sadrži napunjenu štrcaljku.
Humira 40 mg solution for injection in single-use pre-filled syringe (type I glass) with a plunger stopper (bromobutyl rubber) and a needle with a needle shield (thermoplastic elastomer).
Humira 40 mg otopina za injekciju u napunjenoj štrcaljki za jednokratnu primjenu (staklo tipa I), s čepom klipa (bromobutilna guma) i iglom sa zaštitom za iglu (termoplastični elastomer).
Humira 40 mg solution for injection in single-use pre-filled syringe (type I glass) with needleguard for hospital and caregiver use.
Humira 40 mg otopina za injekciju u napunjenoj štrcaljki za jednokratnu primjenu (staklo tipa I) sa štitnikom za iglu za primjenu u bolnicama i od strane njegovatelja.
Humira 40 mg solution for injection in single-use vial (type I glass), fitted with rubber stoppers, aluminium crimps and flip-off seals.
Humira 40 mg otopina za injekciju u bočici za jednokratnu primjenu (staklo tipa I), s gumenim čepom, aluminijskim prstenom i „flip-off“ zatvaračem.
Humira 40 mg solution for injection in vials is supplied as a sterile solution of 40 mg adalimumab dissolved in 0.8 ml solution.
Humira 40 mg otopina za injekciju u bočicama dolazi kao sterilna otopina s 40 mg adalimumaba otopljenog u 0,8 ml otopine.
Humira 40 mg Weekly
Humira 40 mg svaki tjedan
Humira 40 mg/0.8 ml injection Subcutaneous use adalimumab
Humira 40 mg/0,8 ml injekcija Potkožna primjena adalimumab
Humira 40 mg/0.8 ml solution for injection for paediatric use adalimumab
Humira 40 mg/0,8 ml otopina za injekciju za pedijatrijsku uporabu adalimumab
Humira 40 mg/0.8 ml solution for injection for paediatric use.
Humira 40 mg/0,8 ml otopina za injekciju za pedijatrijsku uporabu
Humira also produced a greater improvement in symptoms than placebo (a dummy treatment) in studies of psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis without evidence in the X- ray of ankylosing spondylitis but with objective signs of inflammation, and induction and maintenance phases of treatment for Crohn’s disease, psoriasis and ulcerative colitis.
Lijek Humira također je donio veće poboljšanje simptoma od placeba (prividno liječenje) u ispitivanjima psorijatičnog artritisa, ankilozantnog spondilitisa, aksijalnog spondiloartritisa bez dokaza ankilozantnog spondilitisa na rendgenskim snimkama, ali s objektivnim znakovima upale, i u fazama indukcije i održavanja terapije Crohnove bolesti, psorijaze i ulceroznog kolitisa.
Humira belongs to a group of medicines that block the activity of tumour necrosis factor (TNF) in the body (TNF blockers).
Humira pripada skupini lijekova koji blokiraju aktivnost faktora tumorske nekroze (TNF) u tijelu (TNF blokatori).
Humira can also be used to treat severe, active and progressive rheumatoid arthritis without previous methotrexate treatment.
U svrhu liječenja teškog, aktivnog i progresivnog reumatoidnog artritisa, lijek Humira se može primijeniti i bez prethodnog liječenja metotreksatom.
Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1).
Humira se može davati kao monoterapija u slučajevima nepodnošenja metotreksata ili kada nastavak terapije metotreksatom nije prikladan (za djelotvornost monoterapije vidjeti dio 5.1).
Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.
Humira se može davati i kao monoterapija ako bolesnik ne podnosi metotreksat ili kada kontinuirana primjena metotreksata nije prikladna.
Humira can be taken together with methotrexate or certain disease-modifying anti-rheumatic agents (sulfasalazine, hydroxychloroquine, leflunomide and injectable gold preparations), steroids or pain medications including non-steroidal anti-inflammatory drugs (NSAIDs).
Humira se može primjenjivati istodobno s metotreksatom ili nekim antireumaticima koji mijenjaju tijek bolesti (sulfasalazinom, hidroksiklorokinom, leflunomidom i injekcijskim pripravcima zlata), steroidima ili analgeticima, uključujući i nesteroidne protuupalne lijekove (NSAIL).
Humira can be taken together with methotrexate or certain disease-modifying anti-rheumatic agents (sulfasalazine, hydroxychloroquine, leflunomide and injectable gold preparations), steroids or pain medications including non-steroidal anti-inflammatory drugs (NSAIDs).
Humira se može uzimati istodobno s metotreksatom ili nekim antireumaticima koji mijenjaju tijek bolesti (sulfasalazinom, hidroksiklorokinom, leflunomidom i injekcijskim pripravcima zlata), steroidima, odnosno analgeticima, uključujući i nesteroidne protuupalne lijekove (NSAIL).
Humira can cause reactivation of HBV in people who carry this virus.
Humira može u nositelja virusa uzrokovati reaktivaciju HBV-a.
Humira can reduce the number of nodules and abscesses caused by the disease, and the pain that is often associated with the disease.
Humira može smanjiti broj nodula i apscesa koje uzrokuje bolest te ublažiti bol koja često prati ovu bolest.
Humira can reduce the number of nodules and abscesses you have, and the pain that is often associated with the disease.
Humira može smanjiti broj nodula i apscesa koje imate te ublažiti bol koja često prati ovu bolest.
Humira contains the active substance adalimumab, a selective immuno suppressive agent.
Humira sadrži djelatnu tvar adalimumab koji je selektivni imunosupresiv.
Humira contains the active substance adalimumab, a selective immuno suppressive agent.
Humira sadrži djelatnu tvar adalimumab, koji je selektivni imunosupresiv.
Humira contains the active substance adalimumab, a selective immunosuppressive agent.
Humira sadrži djelatnu tvar adalimumab koji je selektivni imunosupresiv.
Humira contains the active substance adalimumab, which is a human monoclonal antibody.
Humira sadrži djelatnu tvar adalimumab koja je humano monoklonsko protutijelo.
Humira does not contain preservatives.
Humira ne sadrži konzervanse.
Humira has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.
Radiološke su pretrage pokazale da Humira usporava brzinu progresije oštećenja zglobova i poboljšava fizičku funkciju kada se uzima u kombinaciji s metotreksatom.
Humira has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see Section 5.1) and to improve physical function.
Pokazalo se da Humira smanjuje brzinu progresije oštećenja perifernih zglobova mjerene radiološki u bolesnika s poliartikularnim simetričnim podtipovima bolesti (vidjeti dio 5.1) te da popravlja funkciju zglobova.
Humira has not been studied in patients with hepatic or renal impairment
Humira nije ispitivana u bolesnika s oštećenom funkcijom jetre ili bubrega.
Humira is a liquid that is clear and colourless.
Humira je bistra i bezbojna tekućina.
Humira is a medicine that contains the active substance adalimumab.
Humira je lijek koji sadrži djelatnu tvar adalimumab.
Humira is administered by injection under the skin (by subcutaneous injection).
Humira se primjenjuje injekcijom pod kožu (supkutana injekcija).
Humira is administered by injection under the skin (by subcutaneous injection).
Humira se primjenjuje potkožnom injekcijom (supkutana injekcija).
Humira is also available as a pre-filled syringe or a pre-filled pen.
Humira je također dostupna u obliku napunjene štrcaljke ili napunjene brizgalice.
Humira is also used to treat the following patients who have not responded adequately to other treatments or cannot use them:
Humira se također koristi za liječenje sljedećih bolesnika koji nisu na odgovarajući način reagirali na druge terapije ili ih ne mogu koristiti:
Humira is available as a vial, a pre-filled syringe and a pre-filled pen.
Humira je dostupna u obliku bočice, napunjene štrcaljke i napunjene brizgalice.
Humira is available as a vial, a pre-filled syringe, and a pre-filled pen.
Humira je dostupna u obliku bočice, napunjene štrcaljke i napunjene brizgalice.
Humira is available as a vial, a pre-filled syringeand a pre-filled pen.
Humira je dostupna u obliku bočice, napunjene štrcaljke i napunjene brizgalice.
Humira is given as an injection under the skin.
Humira se daje kao supkutana injekcija.
Humira is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic HS therapy.
Humira je indicirana za liječenje umjerenog do teškog oblika aktivnog gnojnog hidradenitisa (acne inversa) u odraslih bolesnika u kojih nije postignut zadovoljavajući odgovor na konvencionalno sistemsko liječenje gnojnog hidradenitisa.
Humira is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and / or MRI, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs.
Humira je indicirana za liječenje teškog oblika aksijalnog spondiloartritisa bez radiološkog dokaza AS-a kod odraslih, ali s objektivnim znakovima upale u obliku povišenog C-reaktivnog proteina (CRP) i/ili nalaza magnetne rezonance (MRI), u kojih nije postignut zadovoljavajući odgovor na nesteroidne protuupalne lijekove (NSAIL) ili koji ih ne podnose.
Humira is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.
Humira je indicirana za liječenje umjerene do teške kronične plak psorijaze u odraslih bolesnika koji su kandidati za sistemsko liječenje.
Humira is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.
Humira je indicirana za liječenje umjerenog do teškog oblika aktivne Crohnove bolesti u pedijatrijskih bolesnika (u dobi od 6 godina i starijih) u kojih nije postignut zadovoljavajući odgovor na konvencionalnu terapiju, uključujući primarnu nutritivnu terapiju i liječenje kortikosteroidom i/ili imunomodulatorom ili u onih koji ne podnose ili u kojih su takve vrste terapija kontraindicirane.
Humira is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.
Humira je indicirana za liječenje neinfektivnog intermedijarnog, posteriornog i panuveitisa u odraslih bolesnika u kojih nije postignut zadovoljavajući odgovor na kortikosteroide, kojima je potrebna poštedna primjena kortikosteroida ili u kojih liječenje kortikosteroidima nije prikladno.
Humira is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.
Humira je indicirana za liječenje teške kronične plak psorijaze u djece i adolescenata u dobi od 4 ili više godina u kojih nije postignut zadovoljavajući odgovor ili koji nisu prikladni kandidati za topikalnu terapiju i fototerapije.
Humira is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.
Humira je indicirana za liječenje umjerenog do teškog oblika aktivne Crohnove bolesti u odraslih bolesnika u kojih unatoč prethodnom potpunom i odgovarajućem tijeku liječenja kortikosteroidima i/ili imunosupresivima nije postignut odgovor ili kod bolesnika koji ih ne podnose ili im je takva terapija kontraindicirana.
Humira is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6- mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.
Humira je indicirana za liječenje umjerenog do teškog oblika aktivnog ulceroznog kolitisa u odraslih bolesnika u kojih nije postignut zadovoljavajući odgovor na konvencionalno liječenje, uključujući kortikosteroide i 6-merkaptopurin (6-MP) ili azatioprin (AZA), ili koji ne podnose ili kod kojih postoje medicinske kontraindikacije za takve terapije.
Humira is injected under the skin (subcutaneous use).
lijek Humira se ubrizgava pod kožu (supkutana primjena).
Humira is intended for treatment of polyarticular juvenile idiopathic arthritis in children 2-17 years, enthesitis-related arthritis in children 6-17 years ,Crohn’s disease in children 6-17 years and plaque psoriasis in children from 4-17 years.
Humira je namijenjena liječenju poliartikularnog juvenilnog idiopatskog artritisa kod djece u dobi 2- 17 godina, artritisa povezanog s entezitisom kod djece u dobi 6-17 godina, Crohnove bolesti kod djece u dobi 6-17 godina i plak psorijaze kod djece u dobi od 4-17 godina.
Humira is intended for treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, enthesitis- related arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of ankylosing spondylitis, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn’s disease, ulcerative colitis and non-infectious uveitis affecting the back of the eye.
Humira je namijenjena liječenju reumatoidnog artritisa, poliartikularnog juvenilnog idiopatskog artritisa, artritisa povezanog s entezitisom, ankilozantnog spondilitisa (AS), aksijalnog spondiloartritisa bez radiološkog dokaza AS-a, psorijatičnog artritisa, psorijaze, gnojnog hidradenitisa (Hidradenitis suppurativa), Crohnove bolesti, ulceroznog kolitisa i nezaraznog uveitisa koji zahvaća stražnji dio oka.
Humira is intended for treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of ankylosing spondylitis, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn’s disease, ulcerative colitis and non-infectious uveitis affecting the back of the eye.
Humira je namijenjena liječenju reumatoidnog artritisa, poliartikularnog juvenilnog idiopatskog artritisa, artritisa povezanog s entezitisom, ankilozantnog spondilitisa (AS), aksijalnog spondiloartritisa bez radiološkog dokaza AS-a, psorijatičnog artritisa, psorijaze, gnojnog hidradenitisa (Hidradenitis suppurativa), Crohnove bolesti, ulceroznog kolitisa i nezaraznog uveitisa koji zahvaća stražnji dio oka.
Humira is used to treat
Humira je namijenjena liječenju
Humira is used to treat adults with moderate to severe plaque psoriasis (a disease causing red, scaly patches on the skin) who need systemic therapy (a treatment given by mouth or injection).
Humira se koristi za liječenje odraslih osoba s umjerenom do teškom plak psorijazom (bolest koja uzrokuje crvene, ljuskave lezije na koži) kojima je potrebno sustavno liječenje (terapija se daje kroz usta ili injekcijom).
Humira is used to treat adults with non-infectious uveitis with inflammation affecting the back of the eye.
Humira je namijenjena liječenju odraslih osoba s nezaraznim uveitisom kod kojega upala zahvaća stražnji dio oka.
Humira is used to treat Crohn’s disease in adults and children aged 6 to 17 years.
Humira je namijenjena liječenju Crohnove bolesti u odraslih i djece u dobi od 6 do 17 godina.